Document is current
Any future updates will be listed below
-
Authors
Wilson, Wyndham H
Young, Ryan M
Schmitz, Roland
Yang, Yandan
Pittaluga, Stefania
Wright, George
Lih, Chih-Jian
Williams, P Mickey
Shaffer, Arthur L
Gerecitano, John
de Vos, Sven
Goy, Andre
Kenkre, Vaishalee P
Barr, Paul M
Blum, Kristie A
Shustov, Andrei
Advani, Ranjana
Fowler, Nathan H
Vose, Julie M
Elstrom, Rebecca L
Habermann, Thomas M
Barrientos, Jacqueline C https://orcid.org/0000-0001-6018-5535
McGreivy, Jesse
Fardis, Maria
Chang, Betty Y
Clow, Fong
Munneke, Brian
Moussa, Davina
Beaupre, Darrin M
Staudt, Louis M
- License Information
-
More Information
Article History
Received: 4 December 2014
Accepted: 22 May 2015
First Online: 20 July 2015
Competing interests
: L.M.S. and J.C.B. have received institutional research funding from Pharmacyclics. L.M.S. and W.H.W. are inventors on a patent application regarding the use of ibrutinib in ABC DLBCL. A.G. has served on advisory boards for Pharmacyclics and Johnson & Johnson and on the speaker's bureau for Johnson & Johnson. N.H.F. has served on advisory board and has received research grants from Pharmacyclics. R.A. has received research grants from Pharmacyclics and Janssen. P.M.B. and J.M.V. have received research grants from Pharmacyclics. R.L.E. is currently an employee of Genentech, Inc. J.M., M.F., B.Y.C., F.C. B.M., D.M., and D.M.B. are employees of Pharmacyclics, Inc. and own stock options. R.M.Y., R.S., Y.Y., S.P., G.W., C.-J.L., P.M.W., A.L.S., J.G., S.d.V., V.P.K., K.A.B., A.S. and T.M.H. declare no competing financial interests.
